- Reviews on hot topics of interest in small molecule drug discovery heavily pursued by industrial research organizations- Provides preclinical information in the context of chemical structures- Knowledgeable section editors who evaluate invited reviews for scientific rigor
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
A Career in Drug Discovery- Natural and Synthetic Neuroactive Steroid (NAS) Modulators of GABAA and NMDA Receptors- Development of LRRK2 Kinase Inhibitors for Parkinson's Disease- Stimulating Neurotrophin Receptors in the Treatment of Neurodegenerative Disorders- Small Molecule Modulators of GPR40 (FFA1)- Recent Advances in the Development of P2Y12 Receptor Antagonists as Antiplatelet Agents- Current Approaches to the Treatment of Atrial Fibrillation- Advances in the Discovery of Small Molecule IRAK4 Inhibitors- H4 Receptor Antagonists and Their Potential Therapeutic Applications- Urate Crystal Deposition Disease and Gout
New Therapies for an Old Problem- p53
MDM2 and MDMX Antagonists- Modulators of Atypical Protein Kinase C as Anticancer Agents- Advancement of Cell Wall Inhibitors in Mycobacterium Tuberculosis- Nucleosides and Nucleotides for the Treatment of Viral Diseases- Advances in Inhibitors of Penicillin Binding Proteins and ß-lactamases as Antibacterial Agents- Tumor Microenvironment as Target in Cancer Therapy- Novel Screening Paradigms for the Identification of Allosteric Modulators and /or Biased Ligands for Challenging G-Protein-Coupled Receptors (GPCRs)- Mer Tyrosine Kinase Receptor: Therapeutic Opportunities in Oncology, Virology and Cardiovascular Indications- Disease Modifying Agents for the Treatment of Cystic Fibrosis- Advancements in Stapled Peptide Drug Discovery and Development- Cytochrome P450 Enzyme Metabolites in Lead Discovery and Development- Case History: ForxigaTM (Dapagliflozin), a Potent Selective SGLT2 Inhibitor for Treatment of Diabetes- Case History: Kalydeco® (VX-770, Ivacaftor), a CFTR Potentiator for the Treatment of Patients with Cystic Fibrosis and the G551D-CFTR Mutation- Case History: XeljanzTM (Tofacitinib Citrate), A First-In-Class Janus Kinase (JAK) Inhibitor for the Treatment of Rheumatoid Arthritis- New Chemical Entities Entering Phase III Trials in 2013- To Market, To Market